Comparative **in vitro–in vivo** correlation analysis with pioglitazone tablets

Sajal Kumar Saha¹*, A. K. Azad Chowdhury¹, Sitesh Chandra Bachar², Sreedam Chandra Das¹, Ruhul H. Kuddus³, Md Aftab Uddin³

¹Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka–1000, Bangladesh
²Department of Pharmaceutical Technology, University of Dhaka, Dhaka–1000, Bangladesh
³Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka–1000, Bangladesh

**Abstract**

**Objective:** To assess the **in vitro–in vivo** correlation of immediate release formulation of pioglitazone 30 mg film coated tablet.

**Methods:** **In vitro** release data were obtained for test and reference formulation using the USP paddle method (Apparatus 2) at 50 r/min and with the temperature of 37°C in the dissolution medium of 0.1 mol/L hydrochloric acid of pH 1.2. Twelve healthy volunteers were administered both test and reference pioglitazone 30 mg tablet orally and blood samples were collected over 24 h period. **In vivo** drug concentrations were analyzed by a simple, fast and precise reverse phase binary HPLC method with UV detection to establish a correlation between **in vitro** release and **in vivo** absorption data.

**Results:** Similarity factor (**f**₂) and dissimilarity factor (**f**₁) were determined for the time intervals of 5, 10, 15, 30, 45, 60, 75, 90, 105 and 120 min and the obtained values were 65.17%, 59.37%, 63.62%, 66.61%, 68.89%, 70.73%, 72.27%, 73.59%, 74.65% and 75.67% for **f**₂ and 9.43%, 9.00%, 5.42%, 3.86%, 3.07%, 2.56%, 2.20%, 1.94%, 1.82% and 1.65% for **f**₁ at respective time intervals. Mean dissolution time for test and reference products were obtained at 3.08 and 3.40 min respectively. **f**₂ and **f**₁ values obtained were within the acceptable range **f**₂ (<15%) and **f**₁ (<15%).

**Conclusions:** Comparison of dissolution profiles corroborate that the test and reference formulations are similar and there is no linear **in vitro–in vivo** correlation.

**Keywords**

**In vitro–in vivo** correlation, Pioglitazone, Immediate release tablets, Similarity factor (**f**₂), Dissimilarity factor (**f**₁)

**1. Introduction**

In recent years, the concept and application of the **in vitro–in vivo** correlation (IVIVC) for pharmaceutical dosage forms have been a main focus of attention of pharmaceutical industry, academia, and regulatory sectors. Development and optimization of formulation is an integral part of manufacturing and marketing of any therapeutic agent which is indeed a time consuming and costly process. Correlation between **in vitro** and **in vivo** data is often used during pharmaceutical development in order to reduce development time and optimize the formulation. After a proper validation, IVIVC predicts the **in vivo** bioavailability results from **in vitro** dissolution data, and this simulation reflects the **in vivo** behavior of the various formulation[s]. The supposition to assure product quality and performance characteristics of immediate release oral solid dosage formulations for specific post approval changes based on the guidance released by the center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA)[2]. According to Scale-Up and Post Approval Changes (SUPAC) immediate release (IR) guidance, a manufacturer will frequently require to demonstrate that the dissolution profiles of the pre-change product and post change product are similar. In Bangladesh, all local manufacturers are yielding generic products by manufacturing process
and equipments modification compared to the innovators products after getting approval from drug administration. Hence it is inevitable to have supplements for SUPAC in both local and generic products. For doing so, we made an attempt to find out the similarity of our local product with generic product and to establish IVIVC of our local product. This present communication deals with the IVIVC of pioglitazone (PTZ) 30 mg tablet with its property to release from the dosage form and in vivo drug performance. SUPAC IR suggests that dissolution profiles may be compared by determining similarity and dissimilarity factor $f_2$ and $f_1$ metric that are recently introduced by Moor and Flanner(3). SUPAC IR also states that an $f_2$ value between 50%-100% suggests that the two dissolution profiles of local and reference formulations are similar[4-6].

PTZ is a thiazolidinedione (TZD) derivative of novel oral hypoglycemic agent for the management of type 2 diabetes mellitus (T2DM)[7-8]. It is one of the peroxisome proliferator–activated receptor (PPAR–γ) agonists that increases transcription of insulin-responsive genes and thus increases insulin sensitivity. It leads to regulation of carbohydrate and lipid metabolism as well as adipocyte differentiation. PTZ stimulates the uptake of glucose and fatty acids into cells by promoting the synthesis and expression of cellular glucose and fatty acid transporters[9,10]. Many studies of PTZ demonstrated the improvement of glycemic control, Hb1c, fasting glucose levels and significant decrease in triglycerides and an increase in high density lipoprotein (HDL) cholesterol levels, with no overall effect on total cholesterol and low density lipoprotein (LDL) cholesterol[11]. In common with other TZDs, PTZ ameliorates insulin resistance associated with T2DM without stimulating insulin release from pancreatic β cell, thus lowering the risk of hypoglycemia[12]. A single dose of 30 mg of PTZ has no hypoglycemic or hypolipidemic effect or liver toxicity within 24 h of treatment among healthy Bengali males[13].

The structural formulation of PTZ hydrochloride is ($\pm$)-5-[p-[2-(5-ethyl-2-pyridyl) ethoxy]-2, 4 thiazolidinedione hydrochloride. The empirical formula is $C_{19}H_{20}N_2O_3S.HCl$. The molecular weight is 392.90. As the case of PTZ, in the fasting state, after oral administration, it was first measurable in serum within 30 min. After absorption from the gastrointestinal tract, peak plasma concentrations were observed within 2 h[14-16]. It was rapidly absorbed within 1 h, achieved peak concentrations at 2–3 h. The absolute bioavailability ranged between 70%-96% with a mean value of 83%. Food slightly delays the time to peak serum concentration 3-4 h, but does not alter the extent of absorption[17,18]. PTZ is highly bound to plasma proteins (>99%) mainly to serum albumin. To a lesser extent, it also binds to other serum proteins[9]. PTZ is metabolized mainly by CYP3A4 and CYP2C8/9[20,21]. PTZ and its metabolites were excreted via urine (15%-30%). The remainders were excreted into bile and feces[9].

2. Materials and methods

2.1. In vitro dissolution test

Six immediate release tablets of each test (Glucozon®, Aristopharma Ltd., Bangladesh) and reference (Actos®, Takeda Pharmaceutical, USA) products of PTZ were taken in the in vitro release kinetic study. The dissolution test was carried out according to the procedure described in the USP paddle method (Apparatus 2). The paddle rotation speed was maintained at 50 r/min at 37 °C. The release test was carried out in 900 mL of dissolution medium (0.1 mol/L hydrochloric acid) using a dissolution tester. Samples of 10 mL were withdrawn at time 0, 5, 10, 15, 30, 45, 60, 75, 90, 105, and 120 min and were analyzed by UV spectrophotometer at a detection wave length 269 nm.

2.2. In vitro absorption study

2.2.1 Subjects

Twelve healthy Bangladeshi adult volunteers ranging in age from 21 to 30 years [mean (23.93±2.73) years], in weight from 58 to 76 kg [mean (61.40±7.98) kg] and height from 166 to 185 cm [mean (164.93±4.87) cm] producing a body mass index (BMI) of 22.57±1.47 were enrolled in this study.

2.2.2. Study design

The study was conducted according to the declaration of Helsinki[22]. Each volunteer signed an informed consent document before entering the study. Ethical permission was taken to approve the protocol and consent form of this study from the institutional ethical review committee (Faculty of Pharmacy, University of Dhaka). Twelve healthy male volunteers randomly received each of test and reference products of a single oral dose of PTZ 30 mg tablet following 15 d wash out period in the in vivo study. Before enrollment, each subject was determined to good health through routine checkup and laboratory tests of medical history, physical examination, electrocardiogram (ECG). No medications were used for at least two weeks before the study. Tobacco and alcohol were forbidden throughout the study, the physical examination was taken again. Exclusion criteria included any history of a significant gastrointestinal condition that could potentially impair the absorption or disposition of the study medicare, previous history of allergy to any medication, donation of blood within 30 d preceding the first dose of the study or use of investigational agent within 30 d of study entry. They were informed about the risk, benefits, procedures and aims of the study as well as their right as research subjects.

2.2.3. Sample collection

Venous blood samples (6 mL) were collected in heparinized tubes at fasting hour and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0, 8.0, 12.0 and 24.0 h after dosing from each subjects. The centrifugations of the collected samples were done at 3000 r/min for 20 min followed by isolation of the plasma. Plasma samples were stored in tubes at ~20 °C until analysis.

2.3. Bioanalytical method

A simple, fast and precise reverse phase binary HPLC (Shimadzu prominence module) method was developed for the separation and quantification of PTZ from plasma. This quantification was carried out using Luna C8 (250 mmX4.6 mm, 5 µm) column (Phenomenex, Torrence, California, USA) and mobile phase comprised of acetonitrile and ammonium acetate (pH 4.5, 20 mmol/L) in proportion of 60:40 (v/v). The flow rate was 1.0 mL/min and the effluent was monitored at 269 nm. The retention time was (6.140±2.2) min. The method was validated in terms of linearity, precision, accuracy, specificity, limit of detection and limit of quantification. In
the interday and intraday assay, the coefficient of variances (CVs) for PTZ was less than 6.4% for all quality control concentrations.

2.4. Data analysis

The area under the plasma concentration–time curve to 24 h (AUC0–24) was determined by the trapezoidal rule, and the area under the serum concentration–time curve extrapolated to infinity (AUC0–∞) for both test and reference products were calculated according to the following formula:

\[
AUC_{0-\infty} = \frac{AUC_{0-t} + C_t}{K_e}
\]

where \(C_t\) is the last quantifiable serum level. The percent of drug absorption was calculated by means of model dependent techniques such as Wagner–Nelson procedure. According to Wagner–Nelson equation,

\[
f_1 = \frac{C_t - K_e\times AUC_0}{K_e\times AUC_0} \times 100
\]

\[
f_2 = \frac{[1+1/n] (R_t - T_t)^{0.5}}{100}
\]

\[
\Delta M = M_{\text{mid}} \times \Delta M / M
\]

where \(M_{\text{mid}}\) is the time at the midpoint between times \(t_i\) and \(t_{i-1}\), and \(\Delta M\) is the amount of drug dissolved between \(t_i\) and \(t_{i-1}\).

3. Results

Dissolution pattern for both test and reference tablets was represented in Table 1. From the graphical presentation, it was observed that the dissolution pattern of reference product was almost similar to that of local product (Figure 1).

Where \(f_2\) and \(f_1\) for reference and test products are also presented in Table 1. Table 1 shows \(f_2\) for 5, 10, 15, 30, 45, 60, 75, 90, 105 and 120 min, and the obtained values were 65.17%, 59.37%, 63.62%, 66.61%, 68.89%, 70.73%, 72.27%, 73.59%, 74.65% and 75.67% for \(f_2\), and 9.43%, 9.00%, 5.42%, 3.86%, 3.07%, 2.56%, 2.20%, 1.94%, 1.82% and 1.65% for \(f_1\) at respective time intervals. The maximum and minimum \(f_2\) values were 75.67% and 59.37%, respectively, which were within the acceptable range of 50%–100%. The maximum value for \(f_1\) was 9.43% which was also within the acceptable range (less than 15%). The percent of drug released were calculated from dissolution profiles and percent of drug absorbed were obtained from the Equation 1 and is shown in Table 2 for both reference and test products.

| Sample | Released (%) |
|--------|-------------|
|        | 5 min | 10 min | 15 min | 30 min | 45 min | 60 min | 75 min | 90 min | 105 min | 120 min |
| **Local (test) Product** | | | | | | | | | | |
| Tab1   | 51.65 | 78.72 | 99.20 | 100.39 | 100.26 | 101.23 | 101.25 | 102.30 | 102.50 | 102.50 |
| Tab2   | 46.13 | 79.23 | 100.21 | 102.15 | 102.25 | 102.50 | 102.42 | 102.50 | 102.50 | 102.30 |
| Tab3   | 48.56 | 80.71 | 101.22 | 101.60 | 102.32 | 102.31 | 102.15 | 102.30 | 102.50 | 102.50 |
| Tab4   | 46.66 | 80.86 | 99.23 | 99.99 | 100.10 | 100.20 | 102.10 | 102.30 | 102.50 | 102.50 |
| Tab5   | 45.58 | 79.86 | 98.86 | 99.98 | 100.28 | 100.25 | 101.76 | 101.56 | 102.53 | 102.11 |
| Tab6   | 44.23 | 78.20 | 99.58 | 100.23 | 100.50 | 100.70 | 100.62 | 100.01 | 100.32 | 100.48 |
| **Mean±SD** | 51.83±2.62 | 79.59±1.07 | 99.33±0.54 | 100.72±0.92 | 100.95±1.04 | 101.19±1.00 | 101.56±0.66 | 101.77±1.09 | 102.20±1.09 | 102.75±0.99 |

| **Reference Product** | | | | | | | | | | |
| Tab1   | 50.84 | 84.98 | 99.89 | 101.23 | 102.40 | 102.89 | 103.80 | 103.20 | 103.40 | 103.50 |
| Tab2   | 52.95 | 88.51 | 100.78 | 101.65 | 100.90 | 101.65 | 101.02 | 101.30 | 101.30 | 101.35 |
| Tab3   | 53.26 | 87.51 | 99.77 | 100.14 | 100.88 | 100.89 | 100.96 | 101.63 | 99.77 | 101.84 |
| Tab4   | 52.65 | 88.01 | 100.83 | 100.95 | 101.20 | 101.35 | 102.40 | 102.10 | 102.10 | 102.08 |
| Tab5   | 52.60 | 87.92 | 101.12 | 101.30 | 102.23 | 102.14 | 102.20 | 101.10 | 101.10 | 101.10 |
| Tab6   | 50.87 | 86.40 | 98.50 | 100.10 | 100.50 | 100.60 | 100.60 | 100.61 | 100.32 | 100.69 |
| **Mean±SD** | 52.04±0.94 | 87.22±1.307 | 99.98±0.85 | 100.89±0.64 | 101.35±0.78 | 101.58±0.83 | 101.83±1.205 | 101.50±0.89 | 101.19±1.24 | 101.76±0.98 |

| Similarity & dissimilarity factor | \(f_1\) (%) | \(f_2\) (%) |
|----------------------------------|------------|------------|
| Tab1                            | 65.17      | 9.43       |
| Tab2                            | 59.37      | 9.00       |
| Tab3                            | 63.62      | 5.42       |
| Tab4                            | 66.61      | 3.86       |
| Tab5                            | 68.89      | 3.07       |
| Tab6                            | 70.73      | 2.56       |
| **Mean±SD**                     | 72.27±2.02 | 1.94±1.82  |

SD: Standard Deviation, \(f_1\) = Dissimilarity factor, \(f_2\) = Similarity factor.
Simulation of percent dissolution data with percent absorption data for both test and reference products followed a nonlinear IVIVC correlation analyzed by level A correlation articulated in Figure 2.

### Table 2
Mean percentage of drug released and absorbed for test and reference product (%).

| Time (min) | Test Drug released | Test Drug absorbed | Reference Drug released | Reference Drug absorbed |
|-----------|--------------------|--------------------|-------------------------|-------------------------|
| 30        | 99.53±0.92         | 11.42±1.51         | 99.98±0.85              | 13.25±1.74              |
| 45        | 100.72±1.04        | 24.59±2.94         | 100.82±1.67             | 27.71±2.99              |
| 60        | 100.95±1.00        | 32.49±2.98         | 101.35±1.43             | 36.56±3.04              |
| 75        | 101.19±0.66        | 41.11±5.96         | 101.58±0.96             | 45.56±5.12              |
| 90        | 101.56±1.09        | 53.65±4.71         | 101.83±1.56             | 60.75±5.71              |
| 105       | 101.72±1.09        | 64.96±4.96         | 101.50±1.69             | 70.97±4.75              |
| 120       | 102.14±0.99        | 71.64±6.32         | 101.19±0.67             | 79.87±6.79              |

Data are expressed as mean±SE.

4. Discussion

An appropriate dissolution conditions could be adapted for routine and in-process quality control of PTZ tablet formulations to ensure *in vivo* performance. It was of interest, therefore, to explore if condition of dissolution of this study, which is very similar to what is proposed by FDA, correlates with serum plasma profiles obtained from bioavailability studies. The dissolution rate for both test and reference products were almost proportionately increased till 30 min. More than 99% dissolution completed as PTZ was IR tablet. The dissolution rate changes were almost stagnant and the dissolution curve followed turning away to the horizontal direction from 30 to 120 min. The simulation of the curve represented that they are similar formulation. On the basis of dissolution efficiencies of the test and reference products, no major differences were found in their dissolution performances. Percent of drug absorption was calculated from the mean serum drug concentrations, using a well-established Wagner–Nelson equation for both reference and local products. The percent of drug release data were plotted against the percent of drug absorption data to press for the IVIVC relationship.

A point–to–point correlation which is the foundation of an acceptable and reliable correlation was achieved but nonlinear. In addition, using the pair–wise procedure based on f2 which is a model independent approach was followed. Level A correlation represents a point–to–point (1:1) relationship between *in vitro* dissolution rate and *in vivo* input rate of the drug from the dosage form which manifested the similar pattern of nonlinear movement for both reference and test products. Primarily rapid rate of dissolution and steeped–up absorption after 30 min for both reference and test products were the basis of nonlinear relationship, PTZ film coated tablet was an IR formulation. As dissolution is not a rate limiting step and absorption can not keep up with dissolution in IR products, the fraction of drug absorbed against the fraction of drug released profile would be nonlinear type which was obtained in our present study.

Aftermath of the present study, it is concluded that test and reference formulations are similar and there is no linear IVIVC correlation between them. Moreover, the findings suggest the bioequivalence which should be carried out as the only reliable and acceptable means to ensure the interchangeability and *in vivo* equivalence of PTZ generic drug products.

**Conflict of interest statement**

The authors declare that there is no conflict of interest.

**Acknowledgements**

Authors would like to acknowledge all the subjects who participated in this study. This study was supported by the Ministry of Science and Information & Communication Technology, People’s Republic of Bangladesh (Grant No. MRC/ERC/2007–2010/2024). Authors are grateful to Prof. Dr. T. K. Pal and his research team, Bioequivalence Study Center, Jadavpur University, Kolkata 700032, India for assistance to the *in vitro*–*in vivo* analysis of the formulations.

**Comments**

**Background**

In recent years, the concept and application of the IVIVC for pharmaceutical dosage forms have been a main focus of attention of pharmaceutical industry, academia, and regulatory sectors. Development and optimization of formulation is an integral part of manufacturing and marketing of any therapeutic agent which is indeed a time consuming and costly process. After a proper validation, IVIVC predicts the *in vivo* bioavailability results from *in vitro* dissolution data, and this simulation reflects the *in vivo* behavior of the various formulations. For doing so, this study made an attempt to find out the similarity of the local product with generic product and to establish IVIVC for local product of PTZ.

**Research frontiers**

Studies are being performed in order to determine the similarities of dissolution profile, *in vivo* drug concentrations at different time interval after administration to 12 healthy volunteers for both test and reference PTZ 30 mg immediate release tablet separately. Eventually simulation of absorption data with dissolution data for both local and generic product is being followed to assess the IVIVC correlation of PTZ.
Related reports
The data regarding peak drug concentration and absorption profile are varied with the Chinese, Japanese, Germany and Tehran population [Souri et al. (2008)]. This variation may be due to ethnic and racial variation, the predominant cause of variation of drug response. But the absorption and dissolution profile are similar for both local and reference products indicate that both formulations are similar. There is no linear IVIVC correlation for both test and reference products. These findings are compatible with many other studies carried out in different countries such as India and Pakistan.

Innovations & breakthroughs
Data regarding IVIVC correlation of PTZ is scanty and this sort of study is the first time for PTZ in Bengali population. This findings have uncovered the in vivo absorption profile of drug is the key to predict the in vivo performance of the drug.

Applications
The findings of the study have significant role in the bioequivalence study to re-ensure the safety profile and reference products indicate that both formulations are similar and there is a nonlinear IVIVC correlation for PTZ IR tablets. Immediate release tablet may lead to this nonlinearity. The results are interesting and suggested that test product may predict the same in vivo drug performance to that of reference products.

References
[1] Cardot JM, Beyssac E. In vitro/in vivo correlations: scientific implications and standardization. Eur J Drug Metab Pharmacokinet 1993; 18(1): 113–120.
[2] Food and Drug Administration, HHS. Immediate release solid oral dosage forms. USA: Food and Drug Administration; 1995. [Online] Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM070636.pdf [Accessed on 12th December, 2012].
[3] Moore JW, Flamer HH. Mathematical Comparison of curves with an emphasis on in–vitro dissolution profiles. Pharm Tech 1996; 20(6): 64–74.
[4] Food and Drug Administration, HHS. Guidance for industry. Extended release oral dosage forms: development, evaluation and application of an in vitro/in vivo correlation. USA: Food and Drug Administration; 1997. [Online] Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm07239.pdf [Accessed on 12th December, 2012].
[5] Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 2001; 220(1–2): 77–83.
[6] Patel HP, Patel JK, Patel MP, Patel RR. Multiple Unit Particles System of Ramipril: An Approach to Enhance Stability. J Young Pharm 2011; 3(2): 90–96.
[7] Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutic perspectives. Diabetes Metab 2007; 33(4): 231–244.
[8] Matsumura T, Taketa K, Shimoda S, Araki E. Thiazolidinedione–independent activation of peroxisome proliferator–activated receptor γ is a potential target for diabetic macrovascular complications. J Diabetes Invest 2012; 3(1): 11–23.
[9] Aroloff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes; a 6–month randomized placebo–controlled dose–response study. The pioglitazone 001 study group. Diabetes Care 2000; 23(11): 1605–1611.
[10] Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60(2): 333–343.
[11] Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi–Benedetti M, Moules IK, et al. Secondary prevention of macro vascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events); a randomized controlled trial. Lancet 2005; 366(9493): 1279–1289.
[12] Madan P. Effect of thiazolidinediones on lipid profile. CMAJ 2005; 173(4): 344.
[13] Saha SK, Das SC, Abdullah–Al–Emran, Sarker M, Uddin MA, Chowdhury AK, et al. Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects. Drug Chem Toxicol 2013; 36(2): 149–154.
[14] Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108(Suppl 2): S234–S242.
[15] Buddle K, Neumayer HH, Fritsche L, Sulowicz W, Stompü T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003; 55(4): 368–374.
[16] Pokhankar V, Kutwal M, Mandpe L. Pioglitazone solid dispersion system prepared by spray drying method: in vitro and in vivo evaluation. PDA J Pharm Sci Technol 2013; 67(1): 23–34.
[17] Lincoff A, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta–analysis of randomized trials. JAMA 2007; 298(10): 1180–1188.
[18] Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006; 66(1): 85–109.
[19] Li J. Peroxisome proliferator–activated receptor (ppar) agonists for type 2 diabetes. In: Johnson DS, Li JJ, editors. In: Johnson DS, Li J, editors. The art of drug synthesis. Holoken: John Wiley and Sons; 2006, p. 115–127.
[20] Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. In: Johnson DS, Li JJ, editors. The art of drug synthesis. Holoken: John Wiley and Sons; 2006, p. 115–127.
[21] Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4. J Pharmacol Exp Ther 2000; 298(2): 666–374.
[22] World Medical Organization. Declaration of Helsinki. Br Med J 1996; 313(7070): 1448–1449.
[23] Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: CRC Press; 1982, p. 433–434.
[24] Nasr M. Celecoxib for oral administration. J Pharm Pharm Sci 2003; 6(3): 1392–1404.
[25] Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharmacol Exp Ther 1964; 53: 1392–1404.
[26] Amann LC, Gandal MJ, Lin R, Liang Y, Siegel SJ. In vitro–in vivo correlations of scalable PLGA–risperidone implants for the treatment of schizophrenia. Pharm Res 2010; 27(8): 1730–1737.
[27] Emami J. In vitro in vivo correlation: from theory to applications. J Pharm Sci 2006; 95(2): 169–189.